Stocks
Raymond James Boosts JNJ Price Target to $265 Amid Strong Q2 Sales
Raymond James analyst Jayson Bedford has maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ) while increasing the price target to $265 from $258. The adjustment reflects a revised valuation outlook for the healthcare conglomerate.
The rating affirmation and target increase highlight the firm's continued confidence in the company's performance trajectory.
Johnson & Johnson raised its full-year 2026 guidance after reporting a 6.6% increase in second-quarter sales to $25.31 billion, driven by robust operational performance across its Innovative Medicine and MedTech segments.